Lupin signs agreement for biosimilar Pegfilgrastim in Brazil

Lupin Limited has signed an exclusive distribution and marketing agreement with Biomm SA for biosimilar Pegfilgrastim in Brazil.

The Indian pharma company had earlier secured the US Food and Drugs Administration (FDA) acceptance of the biologics license application (BLA) for its proposed biosimilar to Neulasta (pegfilgrastim) via a filing using the 3Sl(k) pathway.

Pegfilgrastim is approved for the reduction of the duration of neutropenia as well as the incidents of febrile neutropenia in patients undergoing chemotherapy.